Health Trials

Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Study of LX2006 Gene Therapy in Friedreich Ataxia Cardiomyopathy

The purpose of Study LX2006-03, a multicenter, Phase 2, open-label, randomized, controlled study, is to evaluate the efficacy and safety of LX2006 gene therapy in participants with Friedreich ataxia (FA) cardiomyopathy (CM).

Participants needed: 26
Trial details
Phase: Phase 2Age: 6+Biological sex: AllType: InterventionalSponsor: Lexeo TherapeuticsUpdated: Jul 22, 2026Locations: 1
Eligibility criteria

Male or female, age at least 6 years at the time of signing the informed consent... [+5]

Presence of other forms of cardiomyopathy that contribute to heart failure [+6]

Read more
Status: Recruiting

Clinical Course Of Disease In Participants With FA-CM

Characteristics and clinical course of disease In participants with cardiomyopathy associated with Friedreich Ataxia (CLARITY-FA)

Participants needed: 65
Trial details
Age: 6+Biological sex: AllType: ObservationalSponsor: Lexeo TherapeuticsUpdated: Jun 8, 2026Locations: 19
Eligibility criteria

Male or female, ages ≥6 years at the time of signing the informed consent (and a... [+3]

Presence of other form(s) of CM contributing to heart failure (HF), clinically s... [+7]

Read more
Status: Recruiting

A Study to Assess Real-world Patient Characteristics and Clinical Course for Symptomatic Patients With PKP2-ACM

An observational study to assess real-world patient characteristics and clinical course of disease in participants with PKP2-ACM.

Participants needed: 40
Trial details
Age: 18-65Biological sex: AllType: ObservationalSponsor: Lexeo TherapeuticsUpdated: May 16, 2025Locations: 6Duration: 1 Year
Eligibility criteria

Adults with a clinical diagnosis of ACM as defined by the 2010 revised Task Forc... [+4]

Evidence of variant(s) in addition to PKP2 that meet standard criteria to be con... [+3]

Read more